Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking BioLife’s cryopreservation revenue or CGT logistics risks in a 300-page filing can drain hours. BioLife Solutions insider trading Form 4 transactions hide in dense tables, while critical 8-K updates on clinical-trial shipments surface without warning. If you have ever wondered, “How do I locate BioLife Solutions’ quarterly earnings report 10-Q filing in seconds?” Stock Titan delivers the answer.
Our platform ingests every submission the moment it hits EDGAR and feeds it to an AI engine that turns jargon into clarity. Need a BioLife Solutions annual report 10-K simplified? We highlight consumable sales growth, supply-chain quality metrics, and major risk factors. Looking for BioLife Solutions Form 4 insider transactions real-time? Instant alerts show which executives added shares. The AI also tags each BioLife Solutions proxy statement executive compensation section, unpacks option grants, and links them to performance goals. From BioLife Solutions earnings report filing analysis to a plain-English explainer of every BioLife Solutions 8-K material events explained, the information arrives ready to use.
Professionals rely on these insights to compare consumable-driven gross margins, monitor BioLife Solutions executive stock transactions Form 4 before therapy milestones, and evaluate liquidity through each BioLife Solutions SEC filings explained simply. Whether you are understanding BioLife Solutions SEC documents with AI for the first time or fine-tuning a DCF model, Stock Titan’s real-time coverage, AI-powered summaries, and historical archive of every filing form provide the edge you need—no more hunting through PDFs for the numbers that move CGT markets.
BioLife Solutions (BLFS) reported an insider transaction by its Chief Financial Officer. On 10/09/2025, the CFO executed a sale of 833 shares of common stock at a price of $27.36 per share. Following this transaction, the officer beneficially owns 183,353 shares, held directly.
The filing notes the sale was made pursuant to a Rule 10b5-1(c) trading plan, effective 01/03/2023, to satisfy tax withholding obligations arising from the vesting of restricted stock. This indicates a pre-established, automated plan tied to equity award taxation rather than a discretionary open‑market trade.
BioLife Solutions (BLFS) reported an insider transaction by its Chief Marketing Officer. On October 9, 2025, the officer sold 289 shares of common stock at $27.36 per share. Following the sale, the officer beneficially owned 133,617 shares, held directly. The filing notes the sale was made under a Rule 10b5-1(c) trading plan effective January 3, 2023, established to satisfy tax withholding obligations related to the vesting of restricted stock.
BioLife Solutions (BLFS) insider transaction: EVP & Chief Scientific Officer Aby J. Mathew reported selling 509 shares of common stock at $27.36 on October 9, 2025. The filing states the sale was made under a Rule 10b5-1(c) trading plan effective January 3, 2023, to cover tax withholding tied to restricted stock vesting. After the transaction, he beneficially owns 350,912 shares, held directly. The report was filed by one reporting person.
BioLife Solutions (BLFS) reported an insider transaction by its Chief Human Resources Officer, Sarah Aebersold. On 10/09/2025, she sold 188 shares of common stock at $27.36 per share and now beneficially owns 77,169 shares, held directly. The filing states the sale was executed under a Rule 10b5-1(c) trading plan, effective 01/03/2023, to satisfy tax withholding obligations tied to the vesting of restricted stock.
BioLife Solutions (BLFS) reported an insider transaction by its Chief Quality and Operations officer. On 10/09/2025, the reporting person sold 419 shares of common stock at $27.36 per share in a transaction coded “S.” The filing states this sale was made under a Rule 10b5-1(c) trading plan adopted effective 01-03-2023 to satisfy tax withholding obligations upon the vesting of restricted stock.
Following the sale, the reporting person beneficially owned 193,253 shares, held directly.
Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, reported the disposition of 714 shares of the company's common stock on 09/15/2025 at a price of $25.61 per share. The sale was effected under a Rule 10b5-1 trading plan adopted by the reporting person effective 12/11/2024. After the reported transaction, the reporting person beneficially owned 77,357 shares, held directly. The Form 4 was signed and filed on 09/17/2025, and the filing indicates it was submitted by one reporting person.
Mathew Aby J., EVP & Chief Scientific Officer of BioLife Solutions, Inc. (BLFS), reported a sale of company stock. The filing shows a sale of 630 shares of common stock on 09/11/2025 at a price of $26.83 per share executed under a Rule 10b5-1 trading plan established 03/08/2024 to satisfy tax withholding obligations arising from the vesting of restricted stock. After the reported sale, the reporting person beneficially owned 351,421 shares, held directly. The form is signed by the reporting person on 09/15/2025.
Troy Wichterman, Chief Financial Officer of BioLife Solutions, sold 1,032 shares of common stock on 09/11/2025 at $26.83 per share, reducing his direct holdings to 184,186 shares. The Form 4, signed 09/15/2025, states the sale was made under a Rule 10b5-1 trading plan established 03/08/2024 to cover tax withholding obligations tied to vesting restricted stock. No derivative transactions are reported.
Todd Berard, Chief Marketing Officer of BioLife Solutions, reported a sale of company stock on 09/11/2025. The Form 4 shows he disposed of 358 shares of common stock at a price of $26.83 per share under a Rule 10b5-1 trading plan adopted 03/08/2024 to satisfy tax withholding obligations tied to the vesting of restricted stock. After the transaction, Mr. Berard beneficially owned 133,906 shares directly. The filing is signed and dated 09/15/2025.
Sean Werner, Chief Technology Officer of BioLife Solutions, reported a sale of 72 shares of common stock on 09/11/2025 at $26.83 per share. After the sale he beneficially owns 26,312 shares (direct). The filing states the sale was executed under a Rule 10b5-1 trading plan adopted effective 09/01/2021 to satisfy tax withholding obligations tied to the vesting of restricted stock. The Form 4 is signed 09/15/2025.
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
